Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.40 |
| ▸ | TEK | Q02763 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5642444 | 0.98 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL22593285 | 0.81 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL18878177 | 0.81 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL21567313 | 0.77 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL24466943 | 0.74 | PIP4K2C (0.62) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL13653497 | 0.74 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL12609107 | 0.74 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL1160677 | 0.74 | AXL (0.59) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5455935 | 0.73 | EGFR (0.62) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL4352890 | 0.72 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442777-B2 | Use of substituted oxadiazoles for combating phytopathogenic fungi | BASF SE (DE) | 2019-10-15 | — | — | US | disclosed |
| US-20190016694-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2019-01-17 | — | — | US | disclosed |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2017-05-25 | — | — | US | disclosed |
| EP-2142551-B1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| EP-2142551-B1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-14 | — | — | EP | disclosed |
| US-8546394-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546394-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546394-B2 | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2474549-A1 | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type I inhibitors | Bristol-Myers Squibb Company (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20100144744-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-10 | — | — | US | disclosed |
| US-20100144744-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-10 | — | — | US | disclosed |
| US-20100144744-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-10 | — | — | US | disclosed |
| EP-2142551-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008130951-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130951-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-30 | — | — | WO | disclosed |
| US-7285556-B2 | Thienopyrimidine-based inhibitors of the src family | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMS (US) | 2007-10-23 | — | — | US | disclosed |
| US-20040077663-A1 | Thienopyrimidine-based inhibitors of the src family | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-22 | — | — | US | disclosed |
| EP-1409491-A2 | THIENOPYRIMIDINE-BASED INHIBITORS OF THE SRC FAMILY | Board of Regents, The University of Texas System (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002057271-A2 | THIENOPYRIMIDINE-BASED INHIBITORS OF THE SRC FAMILY | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016694-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, DPM1, NOX1 | PDE4A 2699/4885PDE4B 2017/4885PDE4C 3198/4885 |
| US-20100144744-A1 | FUSED HETEROCYCLIC 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | HSD17B1, HSD11B1, HSD3B1 | PDE4A 2168/4885PDE4B 2485/4885PDE4C 2966/4885 |
| US-10442777-B2 | Use of substituted oxadiazoles for combating phytopathogenic fungi | CYP51A1, DPM1, NOX1 | PDE4A 2699/4885PDE4B 2017/4885PDE4C 3198/4885 |
| US-20040077663-A1 | Thienopyrimidine-based inhibitors of the src family | SRC, LCK, FYN | PDE4A 2821/4885PDE4B 3077/4885PDE4C 3303/4885 |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, DPM1, NOX1 | PDE4A 2699/4885PDE4B 2017/4885PDE4C 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.